MoonLake Immunotherapeutics (MLTX) |
|
54.97 -0.53 (-0.96%)
|
09-27 11:35 |
|
Open: |
55.93 |
Pre. Close: |
55.5 |
|
High:
|
56.8119 |
Low:
|
54.15 |
|
Volume:
|
88,979 |
Market Cap:
|
2,940(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 11:18:33 AM |
|
Short-term rate:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 67.19 One year: 73.22 |
| Support: |
Support1: 49.19 Support2: 40.92 |
| Resistance: |
Resistance1: 57.53 Resistance2: 62.68 |
| Pivot: |
55.03 |
| Moving Average: |
MA(5): 53.94  MA(20): 54.68
MA(100): 45.45 MA(250): 26.6 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 41.4 %D(3): 33.6 |
| RSI: |
RSI(14): 52.3 |
| 52-week: |
High: 63.4 Low: 6.93 |
| Average Vol(K): |
3-Month: 481 (K) 10-Days: 309 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MLTX ] has closed below upper band by 42.4%. Bollinger Bands are 22% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
55.56 - 55.78 |
55.78 - 56.02 |
|
Low:
|
51.86 - 52.09 |
52.09 - 52.34 |
|
Close:
|
55.07 - 55.44 |
55.44 - 55.87 |
|
Company Description |
|
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. |
Headline News |
Tue, 26 Sep 2023
MoonLake Immunotherapeutics Receives 'Moderate Buy' Rating ... - Best Stocks
Mon, 25 Sep 2023
MoonLake Immunotherapeutics (MLTX) Stock Falls -7.16% This Week: Is It a Good Pick? - InvestorsObserver
Mon, 25 Sep 2023
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Average ... - MarketBeat
Tue, 19 Sep 2023
Cantor Fitzgerald Reiterates MoonLake Immunotherapeutics ... - Nasdaq
Mon, 18 Sep 2023
Analyst Remains Bullish on MoonLake Immunotherapeutics MLTX - Best Stocks
Mon, 18 Sep 2023
Best Stocks 2023: These 7 Are Outperforming Nvidia - Investor's Business Daily
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
53 (M) |
| Shares Float |
20 (M) |
|
% Held by Insiders
|
4.8 (%) |
|
% Held by Institutions
|
66 (%) |
|
Shares Short
|
6,660 (K) |
|
Shares Short P.Month
|
6,700 (K) |
Stock Financials |
|
EPS
|
-0.95 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.15 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-11.9 |
|
Return on Equity (ttm)
|
-18.8 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.08 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-42 (M) |
|
Levered Free Cash Flow
|
-23 (M) |
Stock Valuations |
|
PE Ratio
|
-58.72 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
6.08 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-70.82 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
